Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Shares Outstanding (2020 - 2025)

Cytek Biosciences' Shares Outstanding history spans 6 years, with the latest figure at $127.2 million for Q2 2025.

  • For Q2 2025, Shares Outstanding fell 3.29% year-over-year to $127.2 million; the TTM value through Jun 2025 reached $127.2 million, down 3.29%, while the annual FY2023 figure was $130.7 million, 3.44% down from the prior year.
  • Shares Outstanding reached $127.2 million in Q2 2025 per CTKB's latest filing, down from $129.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $136.3 million in Q2 2023 to a low of $31.8 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $120.5 million, with a median of $133.7 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding: soared 6307.03% in 2021, then dropped 4.26% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $133.7 million in 2021, then grew by 1.21% to $135.4 million in 2022, then decreased by 3.44% to $130.7 million in 2023, then fell by 0.73% to $129.8 million in 2024, then dropped by 1.99% to $127.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Shares Outstanding are $127.2 million (Q2 2025), $129.8 million (Q3 2024), and $131.5 million (Q2 2024).